PTH and cancer: Among he secondary endpoints are urinary markers of kidney injury, the dose of methoxypolyethylene glycol epoetin β required to maintain the target haemoglobin level, BP, cardiac biomarkers, left ventricular mass index, acute cellular rejection, bone-turnover markers, intact PTH, bone mineral density, cardiovascular events, all-cause death, and cancer development or recurrence.